Company Profile For AEterna Zentaris, Inc.
Overview
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The Company’s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The products of the Company include Cetrorelix, AEZS-108, Perifosine, Ozarelix, AEZS-112 and AEZS-130. On March 31, 2008, the Company completed the selling of the Company’s product Impavido to Paladin Labs Inc. (Paladin). On March 5, 2009, the Company entered into a development, commercialization and license agreement with sanofi-aventis for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the United States market.
Quick Financial Synopsis
BRIEF: For the six months ended 30 June 2009, AEterna Zentaris Inc.'s revenues decreased 28% to $14.5M. Net loss decreased 19% to $25.5M. Revenues reflect a decrease in sales & royalties and . Net loss was offset by decreased cost of sales, a fall in selling, general & administrative expenses, lower research & development costs, net of tax credits & grants, a fall in intangible assets and lower depreciation & amortization expense.
Company Address
AEterna Zentaris, Inc.
1405 Parc-Technologique Blvd.
Quebec QC G1P 4P5
P: +1418.6528525
F: +1418.6520881
1405 Parc-Technologique Blvd.
Quebec QC G1P 4P5
P: +1418.6528525
F: +1418.6520881
Total Employees
109
Find Out More About AEZ.TO
Market Update
India
US
UK- Asia
- Most Actives
Commodities
| Commodity | Last | Pct Chg | Trade Date/Time |
|---|---|---|---|
| Oil | 78.29 | -0.19% | 11/26 06:49 IST |
| Gold | 1189.0 | +0.17% | 11/26 06:28 IST |
